Last reviewed · How we verify
NCT04948372
Effects of Terlipressin on Renal Perfusion in Patients With Septic Shock
NA trial testing Terlipressin treatment in Septic Shock in 22 participants. Completed in 28 June 2020.
31 May 2020
Quick facts
| Lead sponsor | Southeast University, China |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 1 September 2019 |
| Primary completion | 31 May 2020 |
| Estimated completion | 28 June 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Terlipressin treatment — full drug profile →
- Usual care
Conditions studied
- Septic Shock — all drugs for Septic Shock →
Sponsor
Southeast University, China
Who can join
Adults 18 to 85, any sex, with Septic Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This open-label, randomized controlled trial aimed to investigate the effect of a fixed dose of terlipressin added to usual care vs. usual care alone on renal perfusion in patients with septic shock.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Addition of terlipressin to norepinephrine in septic shock and effect of renal perfusion: a pilot study.
Wang J, Shi M, Huang L, Li Q, et al · · 2022 · cited 18× · PMID 35856162 · DOI 10.1080/0886022x.2022.2095286
Verify or expand the search:
- PubMed search for NCT04948372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Septic Shock
Currently open trials in the same condition.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
- NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting
Other Southeast University, China trials
Trials by the same sponsor.
- NCT07519512 — Effect of Early Transition to Assisted Ventilation on 28-day Successful Extubation in Critically Ill Patients · NA · recruiting
- NCT06990477 — Effect of EIT-guided PEEP in ARDS Patients With Higher Recruitability · NA · recruiting
- NCT07362537 — Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS · NA · recruiting
- NCT07327268 — Cyclic On-off Switching of Pulmonary Blood Flow in Moderate to Severe ARDS · not yet recruiting
- NCT07284888 — Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry- · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04948372 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Southeast University, China
- Last refreshed: 1 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04948372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing